Developer docs
API playgroundTry for free, no card

Search company profiles

TopiVert

Full company profile

uuid000gj6a

Namestring
TopiVert
Websiteurl
topivert.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

TopiVert is a privately-held, London-based biopharmaceutical company founded in 2011 that originated from the Imperial College London innovation ecosystem, with Imperial Innovations serving as the founding lead investor. The company attracted specialized life-sciences venture capital across three funding rounds between 2011 and 2016, raising a disclosed total of approximately $19.9M from Imperial Innovations, SV Health Investors, Johnson & Johnson Development Corporation, and Neomed Management. Leadership consisted of founder Eric Charles Meldrum and Chief Scientific Officer Steve Webber, with headcount in the 11-50 range typical of clinical-stage biotech ventures.

The company's therapeutic focus, specific pipeline assets, and underlying technology platform are not disclosed in the available source data; no products, services, clinical programs, patents, or partnerships are described beyond investor participation. The most recent source signal indicates that the company's primary web domain, topivert.com, is currently listed for sale on HugeDomains for $10,595 and hosts no operational content, which suggests the entity is no longer actively maintaining a digital presence. There is no disclosed revenue model, pricing mechanism, go-to-market motion, or customer base in the source material.

Short descriptiontext

TopiVert is a London-based, privately-held biopharmaceutical venture founded in 2011, spun out of the Imperial College London ecosystem and backed by specialized life-sciences investors across three funding rounds through 2016; the company's current operational status is unclear, with its primary domain listed for sale.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
topical therapeutics, inflammatory disease research, gastrointestinal drug development, clinical-stage biopharmaceuticals, university-sourced life sciences
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage biopharmaceutical R&D
Social media profiles2 records
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TopiVert developed and advanced clinical-stage, topical therapeutic candidates targeting inflammatory diseases of the gastrointestinal tract, leveraging pioneering university-originated biopharmaceutical technology. The company's work was structured around translational drug discovery and early-stage clinical development intended to support licensing or partnership deals with larger pharmaceutical firms.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product or service information for TopiVert is available in the source data. The only TopiVert-related webpage identified is a domain for sale page (topivert.com) hosted by HugeDomains, which contains no information about the company's actual products, services, or technology offerings.

Product and service1 record
1Topical therapeutic pipeline for inflammatory GI disease
CategoryClinical-stage biopharmaceutical R&D
Description

A pipeline of topical therapeutic candidates intended for treatment of inflammatory diseases of the gastrointestinal tract, developed for eventual in-licensing, partnership, or further development by larger pharmaceutical companies. Targeted at pharmaceutical partners rather than end consumers.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

CRO and clinical research organization specialized in inflammatory bowel disease and gastrointestinal clinical trials. TopiVert developed therapeutics in the same IBD/GI specialty area, making Alimentiv a directly comparable peer in trial execution and disease focus.

TypeDirect peer
Description

European clinical-stage biotech developing oral small-molecule therapies for inflammatory diseases including ulcerative colitis. Closely comparable to TopiVert in therapeutic area (IBD/GI inflammation), modality (small molecules), and stage of development.

3Morphic Therapeutic
TypeDirect peer
Description

Clinical-stage biotech developing oral integrin inhibitors for autoimmune and inflammatory diseases including IBD. Directly comparable in target space, modality, and indication overlap with TopiVert's inflammatory disease focus.

TypeDirect peer
Description

Specialty pharma focused on gastrointestinal and cardiorenal diseases, with approved and pipeline assets in IBS-C, hyperphosphatemia, and related GI conditions. Comparable as a specialty GI therapeutics developer with similar scale and strategic focus.

TypeDirect peer
Description

GI-focused specialty pharma commercializing Linzess for IBS-C/CIC and developing additional GI assets. Comparable in therapeutic area focus and small-molecule GI drug development model.

TypeDirect peer
Description

Specialty pharma with marketed GI products (e.g., Talicia, Aemcolo) and a pipeline addressing H. pylori, IBS, and other GI conditions. Directly comparable in GI therapeutic focus and small-molecule development strategy.

TypeDirect peer
Description

Specialty pharma with legacy GI/opioid-induced constipation franchise and inflammatory disease pipeline. Comparable in specialty pharma positioning, GI therapeutic area, and small-molecule development history.

TypeBroad incumbent
Description

European clinical-stage biotech with a broad inflammation/immunology pipeline including IBD candidates (filgotinib, Jyseleca). Comparable as a larger European inflammation player overlapping with TopiVert's therapeutic area.

9Prometheus Biosciences (now Merck)
TypeBroad incumbent
Description

Was a clinical-stage immunology company focused on IBD (acquired by Merck for ~$10.8B in 2023). Comparable as a peer IBD-focused biotech that successfully exited via large-pharma acquisition — useful as a comparable exit scenario.

TypeOthers
Description

Specialist healthcare venture and growth investor and a key backer of TopiVert. Listed as a peer for ecosystem reference rather than direct competition; relevant as a repeat co-investor in the European specialty pharma space.

Market position
Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TopiVert

Clinical-stage biopharmaceutical R&Dtopivert.com

TopiVert is a London-based, privately-held biopharmaceutical venture founded in 2011, spun out of the Imperial College London ecosystem and backed by specialized life-sciences investors across three funding rounds through 2016; the company's current operational status is unclear, with its primary domain listed for sale.

What TopiVert does

TopiVert is a privately-held, London-based biopharmaceutical company founded in 2011 that originated from the Imperial College London innovation ecosystem, with Imperial Innovations serving as the founding lead investor. The company attracted specialized life-sciences venture capital across three funding rounds between 2011 and 2016, raising a disclosed total of approximately $19.9M from Imperial Innovations, SV Health Investors, Johnson & Johnson Development Corporation, and Neomed Management. Leadership consisted of founder Eric Charles Meldrum and Chief Scientific Officer Steve Webber, with headcount in the 11-50 range typical of clinical-stage biotech ventures.

The company's therapeutic focus, specific pipeline assets, and underlying technology platform are not disclosed in the available source data; no products, services, clinical programs, patents, or partnerships are described beyond investor participation. The most recent source signal indicates that the company's primary web domain, topivert.com, is currently listed for sale on HugeDomains for $10,595 and hosts no operational content, which suggests the entity is no longer actively maintaining a digital presence. There is no disclosed revenue model, pricing mechanism, go-to-market motion, or customer base in the source material.

TopiVert firmographics

Firmographics
Name
TopiVert
Website
https://topivert.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
TopiVert is a London-based, privately-held biopharmaceutical venture founded in 2011, spun out of the Imperial College London ecosystem and backed by specialized life-sciences investors across three funding rounds through 2016; the company's current operational status is unclear, with its primary domain listed for sale.
Ownership category
akta.pro rank

TopiVert industry classification

Industry
Product category
Clinical-stage biopharmaceutical R&D
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Topical therapeutics
  • Inflammatory disease research
  • Gastrointestinal drug development
  • Clinical-stage biopharmaceuticals
  • University-sourced life sciences

Where TopiVert is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

TopiVert business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

TopiVert product offering

Product offering

Core offering

TopiVert developed and advanced clinical-stage, topical therapeutic candidates targeting inflammatory diseases of the gastrointestinal tract, leveraging pioneering university-originated biopharmaceutical technology. The company's work was structured around translational drug discovery and early-stage clinical development intended to support licensing or partnership deals with larger pharmaceutical firms.

Product overview

No product or service information for TopiVert is available in the source data. The only TopiVert-related webpage identified is a domain for sale page (topivert.com) hosted by HugeDomains, which contains no information about the company's actual products, services, or technology offerings.

Differentiator

Problem solved

Functional benefit

Products and services

  • Topical therapeutic pipeline for inflammatory GI disease A pipeline of topical therapeutic candidates intended for treatment of inflammatory diseases of the gastrointestinal tract, developed for eventual in-licensing, partnership, or further development by larger pharmaceutical companies. Targeted at pharmaceutical partners rather than end consumers.

Companies that use TopiVert

Customer profile

Ideal customer profiles1 record

TopiVert technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TopiVert partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights3 records

TopiVert competitors and assessment

Company assessment

Direct peers

  • Alimentiv (formerly Robarts Clinical Trials): CRO and clinical research organization specialized in inflammatory bowel disease and gastrointestinal clinical trials. TopiVert developed therapeutics in the same IBD/GI specialty area, making Alimentiv a directly comparable peer in trial execution and disease focus.
  • Abivax: European clinical-stage biotech developing oral small-molecule therapies for inflammatory diseases including ulcerative colitis. Closely comparable to TopiVert in therapeutic area (IBD/GI inflammation), modality (small molecules), and stage of development.
  • Morphic Therapeutic: Clinical-stage biotech developing oral integrin inhibitors for autoimmune and inflammatory diseases including IBD. Directly comparable in target space, modality, and indication overlap with TopiVert's inflammatory disease focus.
  • Ardelyx: Specialty pharma focused on gastrointestinal and cardiorenal diseases, with approved and pipeline assets in IBS-C, hyperphosphatemia, and related GI conditions. Comparable as a specialty GI therapeutics developer with similar scale and strategic focus.
  • Ironwood Pharmaceuticals: GI-focused specialty pharma commercializing Linzess for IBS-C/CIC and developing additional GI assets. Comparable in therapeutic area focus and small-molecule GI drug development model.
  • RedHill Biopharma: Specialty pharma with marketed GI products (e.g., Talicia, Aemcolo) and a pipeline addressing H. pylori, IBS, and other GI conditions. Directly comparable in GI therapeutic focus and small-molecule development strategy.
  • Theravance Biopharma: Specialty pharma with legacy GI/opioid-induced constipation franchise and inflammatory disease pipeline. Comparable in specialty pharma positioning, GI therapeutic area, and small-molecule development history.

Broad incumbents

  • Galapagos NV: European clinical-stage biotech with a broad inflammation/immunology pipeline including IBD candidates (filgotinib, Jyseleca). Comparable as a larger European inflammation player overlapping with TopiVert's therapeutic area.
  • Prometheus Biosciences (now Merck): Was a clinical-stage immunology company focused on IBD (acquired by Merck for ~$10.8B in 2023). Comparable as a peer IBD-focused biotech that successfully exited via large-pharma acquisition — useful as a comparable exit scenario.

Others

  • SV Health Investors (formerly SV Life Sciences): Specialist healthcare venture and growth investor and a key backer of TopiVert. Listed as a peer for ecosystem reference rather than direct competition; relevant as a repeat co-investor in the European specialty pharma space.

Market position

Weaknesses3 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

TopiVert social profiles

Digital presence

TopiVert financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TopiVert leadership team

Management profile

Number of profiles

Profiles2 records

TopiVert funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TopiVert M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TopiVert

What does TopiVert do?

TopiVert developed and advanced clinical-stage, topical therapeutic candidates targeting inflammatory diseases of the gastrointestinal tract, leveraging pioneering university-originated biopharmaceutical technology. The company's work was structured around translational drug discovery and early-stage clinical development intended to support licensing or partnership deals with larger pharmaceutical firms.

When was TopiVert founded?

TopiVert was founded in 2011. It employs 1 to 10 people.

Where is TopiVert based?

TopiVert is headquartered in London, United Kingdom, in the Europe region.

Who are TopiVert's main competitors?

Direct peers on record are Alimentiv (formerly Robarts Clinical Trials), Abivax, Morphic Therapeutic, Ardelyx, Ironwood Pharmaceuticals, RedHill Biopharma and Theravance Biopharma. Broad incumbents are Galapagos NV and Prometheus Biosciences (now Merck). SV Health Investors (formerly SV Life Sciences) is listed as an others.

Does TopiVert have an API?

No public API is recorded for TopiVert.

What industry is TopiVert in?

TopiVert's product category is Clinical-stage biopharmaceutical R&D. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTopiVert Pharma Limited: Positive results from TOP1288 Phase 1 studyTopiVert Pharma announced positive Phase 1 results for its oral TOP1288 formulation for ulcerative colitis, showing drug delivery to colon tissue up to 36 hours after dosing. The study confirmed safety and tolerability with minimal systemic absorption, and the company plans to progress to a proof of concept study.GlobeNewswireTopiVert Pharma Limited: TopiVert completes TOP1630 preclinical developmentTopiVert Pharma completed preclinical development of TOP1630, a topical anti-inflammatory for dry eye disease, and plans to submit an IND to the FDA in H2 2016. A Phase I/II study is on track to start in the US in early 2017, with results expected by mid-2017.VC News DailyTopiVert Snares $12.52MImperial Innovations Group and SV Life Sciences have committed to invest £8 million ($12.52 million) in a new start-up company TopiVert, which will focus on developing topical medicines for inflammatory diseases of the eye and gut. TopiVert has licensed NSKI (narrow spectrum kinase inhibitor) intellectual property from RespiVert Ltd., a former Imperial Innovations portfolio company acquired by Janssen Biotech in 2010, and will enter into an exclusive drug discovery collaboration with RespiVert. The funding will support development of treatments for conditions including uveitis and inflammatory bowel disease, with market projections showing the IBD market rising from $3.5bn in 2009 to $5.6bn by 2019.